Table 1.
Main characteristics of the eligible studies.
| Eligible Study | Year | Country | Caner type | Sample size | Median age (range) | Follow-up time (months) |
Assay method | Therapy | HEV marker | Cutoff criteria | Survival outcome | Source of HR | Study design |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Martinet L et al. (10) | 2011 | France | Breast cancer | 146 | NR | 122 | IHC | Surgery | MECA-79 | The highest tercile vs. 2 lowest terciles | OS; DFS | Reported | Retrospective |
| Okayama H et al. (12) | 2011 | Japan | Gastric cancer | 250 | NR | 83 (1.7–213.6) | IHC | Surgery | MECA-79 | More than 5% | CSS | Reported | Retrospective |
| Wirsing AM et al. (16) | 2016 | Korea | OSCC | 108 | 42(23- 70) | NR | IHC | Surgery | MECA-79 | Median value | CSS | Reported | Retrospective |
| Song IH et al. (17) | 2017 | Korea | TNBC | 108 | 42(23-70) | 31.4(21.1-53.0) | IHC | NAC and surgery | MECA-79 | NR | DFS | Reported | Retrospective |
| Sebestyén T et al. (18) | 2018 | Hungary | Melanoma | 118 | NR | NR | IHC | Surgery | MECA-79 | Median value | DFS; OS | Survival curve | Retrospective |
| Hong SA et al. (19) | 2020 | Korea | Gastric Cancer | 157 | 66.3 (35–92) | 43 | IHC | Surgery | MECA-79 | Present vs. absent | OS | Reported | Retrospective |
| Karpathiou G et al. (20) | 2021 | France | HNSCC | 135 | 62.2 (40-86) | NR | IHC | NAC or surgery | MECA-79 | Mean value | OS; PFS | Survival curve | Retrospective |
| Park HS et al. (21) | 2021 | Korea | Gastric cancer | 452 | NR | NR | IHC | Surgery | MECA-79 | Median value | OS; RFS | Reported | Retrospective |
| Li H et al. (22) | 2022 | China | ESCC | 52 | 59(44-76) | NR | IHC | Surgery | MECA-79 | Median score | OS | Survival curve | Retrospective |
| Asrir A et al. (23) | 2022 | France | Melanoma | 93 | NR | NR | IHC | Anti-PD-1 combined with anti-CTLA-4 Thepapy | MECA-79 | TA-HEV scores 3 or 2 | OS; PFS | Survival curve | Retrospective |
| Karpathiou G et al. (24) | 2022 | France | Endometrial cancer | 40 | 62.5 (33–90) | 24 (24-168) | IHC | Surgery | MECA-79 | Present vs. absent | NR | NR | Retrospective |
| Zhan Z et al. (25) | 2023 | China | Colorectal cancer | 203 | NR | 50 (0–72) | IHC | Surgery | MECA-79 | Mean value | OS; DFS | Reported | Retrospective |
| Hyytiäinen A et al. (26) | 2023 | Finland | OSCC | 71 | 61 | 39 (0 –97) | IHC | Surgery adjuvant RT or CRT | MECA-79 | Median value | DFS | Survival curve | Retrospective |
TNBC, triple-negative breast cancer; ESCC, esophageal squamous cell carcinoma; OSCC, oral tongue squamous cell carcinoma; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; CSS, cancer-specific survival; NR, not reported; IHC, immunohistochemistry; NAC, neoadjuvant chemotherapy; PD-1, Programmed death-1; CTLA-4, cytotoxic T lymphocyte–associated protein 4; RT, radiotherapy; CRT, chemoradiotherapy.